Impact of apolipoprotein E on Alzheimer's disease

scientific article

Impact of apolipoprotein E on Alzheimer's disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2174/15672050113109990156
P8608Fatcat IDrelease_j32clc5ilrhy5fgnpwmickt7ee
P932PMC publication ID3995977
P698PubMed publication ID23919769

P50authorRobert O. RyanQ57668754
P2093author name stringPaul S Hauser
P2860cites workApolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's diseaseQ22248091
Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicityQ24291110
Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregationQ24291128
The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteinsQ24297456
The Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motifQ24600203
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse modelsQ24628845
ApoE promotes the proteolytic degradation of AbetaQ24651102
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer diseaseQ26858870
Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein EQ27663468
Topology of human apolipoprotein E3 uniquely regulates its diverse biological functionsQ27672294
Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoformsQ27730887
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset familiesQ27860677
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeuticsQ27860914
ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteinsQ28140079
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer diseaseQ28238269
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's diseaseQ28294536
Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brainQ28477020
LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteinsQ28595076
Isoform-specific binding of apolipoprotein E to beta-amyloidQ28596589
Decreased clearance of CNS beta-amyloid in Alzheimer's diseaseQ29616534
Apolipoprotein E4 domain interaction: synaptic and cognitive deficits in miceQ30486146
ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 miceQ30497102
Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicityQ33398425
Molecular basis of exchangeable apolipoprotein functionQ33796767
Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 miceQ33906674
Lipoproteins in the central nervous systemQ33922696
Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons.Q34096644
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3Q34229659
Apolipoprotein E: From lipid transport to neurobiologyQ34497951
Abnormal in vivo metabolism of apolipoprotein E4 in humansQ34539465
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE.Q44989710
Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptideQ45738154
Lipid-induced extension of apolipoprotein E helix 4 correlates with low density lipoprotein receptor binding ability.Q45930842
Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice.Q45993868
Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE.Q46001228
Interaction with amyloid beta peptide compromises the lipid binding function of apolipoprotein E.Q46067044
Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levelsQ46262337
Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domainsQ46421943
Fluorescence resonance energy transfer analysis of apolipoprotein E C-terminal domain and amyloid beta peptide (1-42) interactionQ46478601
Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteinsQ46656933
The structure of human apolipoprotein E2, E3 and E4 in solution 1. Tertiary and quaternary structure.Q46684770
The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease.Q46738144
Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer diseaseQ46738145
Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 miceQ46738149
Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.Q46740358
Medicine. Old drug, new hope for Alzheimer's diseaseQ47570227
Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouseQ48024701
Apolipoprotein E and Alzheimer's disease. The tip of the susceptibility icebergQ48293119
Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's diseaseQ49168963
Molecular dynamics simulation and computational two-dimensional infrared spectroscopic study of model amyloid β-peptide oligomers.Q51021433
Protective effect of apoE epsilon 2 in Alzheimer's disease.Q53314590
Lipid binding-induced conformational changes in the N-terminal domain of human apolipoprotein E.Q53940110
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteinsQ68921833
The low density lipoprotein receptor active conformation of apolipoprotein E. Helix organization in n-terminal domain-phospholipid disc particlesQ77332976
Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free formsQ80996400
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer diseaseQ34662682
Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's diseaseQ34960461
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's diseaseQ35084110
An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from gliaQ35152189
Nuclear receptors as therapeutic targets for Alzheimer's diseaseQ35165186
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic miceQ35978742
Purified and synthetic Alzheimer's amyloid beta (Aβ) prionsQ36079533
Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic miceQ36206696
Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's diseaseQ36208400
Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognitionQ36304858
Assembly of high-density lipoproteinQ36311786
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.Q36383616
Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptideQ36384642
APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.Q36451896
The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegenerationQ37017266
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neuronsQ37117670
PPARgamma agonists as therapeutics for the treatment of Alzheimer's diseaseQ37215869
Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structureQ37307244
Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E.Q37497056
Clusterin: a forgotten player in Alzheimer's diseaseQ37570713
Understanding the basis for the association of apoE4 with Alzheimer's disease: opening the door for therapeutic approachesQ37623844
Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's diseaseQ37676477
Clusterin in Alzheimer's diseaseQ37991343
Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactionsQ38353402
Preventing Alzheimer's diseaseQ39549596
Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer diseaseQ39625718
24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expressionQ40209163
Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosisQ40374258
Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transferQ40571686
A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytesQ40599853
Apolipoprotein E: structure-function relationshipsQ40737965
The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteinsQ40737971
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's diseaseQ40849918
Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptidesQ40879124
Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.Q41671941
Cell biology. A unifying role for prions in neurodegenerative diseasesQ41997625
Lipid association-induced N- and C-terminal domain reorganization in human apolipoprotein E3.Q43694392
Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic miceQ43752025
Domain structure and lipid interaction in human apolipoproteins A-I and E, a general modelQ44412885
Reduced levels of human apoE4 protein in an animal model of cognitive impairmentQ44601281
Helix orientation of the functional domains in apolipoprotein e in discoidal high density lipoprotein particlesQ44739118
Transformation of amyloid β(1-40) oligomers into fibrils is characterized by a major change in secondary structureQ44808414
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectAlzheimer's diseaseQ11081
P304page(s)809-17
P577publication date2013-10-01
P1433published inCurrent Alzheimer ResearchQ5195031
P1476titleImpact of apolipoprotein E on Alzheimer's disease
P478volume10

Reverse relations

cites work (P2860)
Q30402554A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions
Q92717013A transient reporter for editing enrichment (TREE) in human cells
Q56999989APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s Pathogenesis
Q37280174Alzheimer's disease: presence and role of microRNAs
Q35327172Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis
Q38543425Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights
Q38256360Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease
Q35823248ApoE4-specific Misfolded Intermediate Identified by Molecular Dynamics Simulations
Q48217870Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease
Q41691286Apolipoprotein E epsilon 4 (APOE-ε4) genotype is associated with decreased 6-month verbal memory performance after mild traumatic brain injury
Q34410256Apolipoprotein E gene polymorphism and Alzheimer's disease in Chinese population: a meta-analysis
Q53627025Apolipoprotein E levels in pediatric patients undergoing cardiopulmonary bypass.
Q94474496Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework
Q40047305Association between dietary patterns and cognitive function among 70-year-old Japanese elderly: a cross-sectional analysis of the SONIC study.
Q47162013Association of HLA-DRB1 polymorphism with Alzheimer's disease: a replication and meta-analysis
Q40135749Association of Parkinson's Disease GWAS-Linked Loci with Alzheimer's Disease in Han Chinese
Q47270627Atomistic Insights into Structural Differences between E3 and E4 Isoforms of Apolipoprotein E.
Q89467928BIG-TREE: Base-Edited Isogenic hPSC Line Generation Using a Transient Reporter for Editing Enrichment
Q50563445Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer's Disease.
Q26784555Biochemical Markers of Physical Exercise on Mild Cognitive Impairment and Dementia: Systematic Review and Perspectives
Q52631118Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion.
Q64273242Drug Development for Alzheimer's Disease: Microglia Induced Neuroinflammation as a Target?
Q36885357Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit
Q57191644Generation and characterization of two human induced pluripotent stem cell (hiPSC) lines homozygous for the Apolipoprotein e4 (APOE4) risk variant-Alzheimer's disease (ASUi005-A) and healthy non-demented control (ASUi006-A)
Q42323951Helical structure, stability, and dynamics in human apolipoprotein E3 and E4 by hydrogen exchange and mass spectrometry.
Q64945257Hidden Aggregation Hot-Spots on Human Apolipoprotein E: A Structural Study.
Q87469994Hyperactive glial cells contribute to axonal pathologies in the spinal cord of Npc1 mutant mice
Q33837891Identification of misdiagnosed fronto-temporal dementia using APOE genotype and phenotype-genotype correlation analyses.
Q33807188Influence of domain stability on the properties of human apolipoprotein E3 and E4 and mouse apolipoprotein E.
Q38543419Lipids in Amyloid-β Processing, Aggregation, and Toxicity
Q35507433Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA.
Q64076664MicroRNAs in Alzheimer's Disease
Q47794190Molecular Mechanisms of the R61T Mutation in Apolipoprotein E4: A Dynamic Rescue
Q38183429Nutrition in early life and the programming of adult disease: a review.
Q38562084Promising Targets for the Treatment of Neurodegenerative Diseases
Q34992525Quantitative proteomics identifies host factors modulated during acute hepatitis E virus infection in the swine model
Q35158382SIRT1 in the brain-connections with aging-associated disorders and lifespan
Q36031087Structural stability and functional remodeling of high-density lipoproteins.
Q31140102The effectiveness and unique contribution of neuropsychological tests and the δ latent phenotype in the differential diagnosis of dementia in the uniform data set.

Search more.